The NPM1 mutation, typically a favorable prognostic marker in newly diagnosed AML, loses this advantage in the relapsed/refractory setting. Survival for relapsed NPM1 patients becomes as poor as for those without the mutation, justifying aggressive targeted therapy with menin inhibitors.

Despite impressive data supporting HMA/Venetoclax, its application in younger, fit patients must be cautious. The pivotal VIALE-A trial excluded key subgroups like FLT3, core binding factor, and certain NPM1 patients, for whom intensive chemotherapy remains the standard.

Menin inhibitors achieve high rates of MRD-negative remissions. However, the median duration is very short (4-6 months), suggesting current MRD assays may not adequately capture residual disease and that "MRD negativity" is not a reliable predictor of long-term benefit for this drug class.

Despite clinical efficacy, menin inhibitor monotherapy provides a relatively short duration of response (4-6 months) in the relapsed/refractory setting. Their main clinical benefit is achieving a deep enough remission to allow patients to proceed to a potentially curative allogeneic stem cell transplant.

When an AML patient presents with multiple targetable mutations (FLT3, NPM1, IDH), clinicians follow a treatment hierarchy. FLT3-targeted therapy is typically the first choice due to its aggressive phenotype. Menin inhibitors for NPM1 are next, followed by IDH inhibitors, guiding treatment decisions in complex cases.

While quizartinib's benefit is less pronounced in AML patients over 60, a specific genomic signature—the co-occurrence of FLT3-ITD, NPM1, and DNMT3A mutations—identifies a subset of older patients who derive a significant survival benefit, challenging age-based treatment decisions.

A key nuance in managing ponatinib for Ph+ ALL is a response-adapted dosing strategy. Patients are typically started at a 30mg dose, which is then reduced to 15mg once a good minimal residual disease (MRD) response is achieved. This approach aims to maintain efficacy while mitigating long-term toxicity.

The Spanish KIWI trial showed a surprising survival benefit for quizartinib in FLT3-ITD negative AML. The benefit was greatest in patients with NPM1 and DNMT3A mutations, suggesting the drug's efficacy extends beyond its primary target through other mechanisms.

Standard cytogenetics miss complex genetic rearrangements. Advanced techniques like Optical Genome Mapping (OGM) are identifying "cryptic" fusions (e.g., involving KMT2A, NUP98) in patients who appear to be wild-type. This expands the eligible patient pool for menin inhibitors beyond those with classic mutations.